---
schema_version: "secwatch.filing_event.v1"
accession: "0000914475-24-000033"
form_type: "8-K"
ticker: "NBIX"
cik: "0000914475"
company_name: "NEUROCRINE BIOSCIENCES INC"
filed_at: "2024-02-07T23:59:59+00:00"
generated_at: "2026-06-06T07:35:26.566847+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Neurocrine Q4 INGREZZA sales $500M (+25% YoY); FY 2024 guidance $2.1-$2.2B

## Summary
- Q4 GAAP net income $147.7M ($1.44 diluted EPS) vs $89M ($0.88) in Q4 2022; non-GAAP EPS $1.54.
- Full-year 2023 INGREZZA net product sales $1.84B (+29% YoY); total revenue $1.89B.
- FY 2024 INGREZZA sales guidance $2.1–$2.2B; GAAP R&D $645–$675M, SG&A $930–$950M.
- Patent litigation resolved; generic INGREZZA entry no earlier than March 2038.
- Crinecerfont FDA submission for congenital adrenal hyperplasia expected Q2 2024.

## SEC filing metadata
- accession: 0000914475-24-000033
- form_type: 8-K
- ticker: NBIX
- cik: 0000914475
- company_name: NEUROCRINE BIOSCIENCES INC
- filed_at: 2024-02-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/914475/000091447524000033/0000914475-24-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/914475/000091447524000033/nbix-20240207.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914475-24-000033
- JSON: https://secwatch.observer/filing/0000914475-24-000033.json
- Plain text: https://secwatch.observer/filing/0000914475-24-000033.txt

## Key facts
- Earnings Releases
  NEUROCRINE BIOSCIENCES INC updated its the fourth quarter and fiscal year ended December 31, 2023 guidance (reaffirmed).
  - Period: the fourth quarter and fiscal year ended December 31, 2023
  - Guidance: reaffirmed
  - Result: reported results
  source text: On February 7, 2024, Neurocrine Biosciences, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/914475/000091447524000033/0000914475-24-000033-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.